Core Insights - The newly released "Commercial Health Insurance Innovative Drug Directory (2025)" marks the first of its kind in China, focusing on high-innovation drugs that exceed the basic medical insurance's scope [1][2] Group 1: Overview of the Commercial Health Insurance Innovative Drug Directory - The directory was developed by the National Healthcare Security Administration and includes high-priced innovative drugs, gene therapies, and specific rare disease treatments [1] - A total of 121 drug names were reviewed, with 19 drugs from 18 innovative pharmaceutical companies successfully included, resulting in an acceptance rate of approximately 15.7% [1] Group 2: Focus on Rare Diseases and Cancer Treatments - The directory includes drugs for Alzheimer's disease and rare diseases prevalent in children, such as Gaucher disease and neuroblastoma [2] - North Sea Kangcheng's Gaucher drug, the first domestically developed enzyme replacement therapy, was approved for use in patients aged 12 and older [2] Group 3: Impact on CAR-T Therapy - Five domestic CAR-T products were included in the directory, which is expected to significantly reduce patient out-of-pocket expenses and improve accessibility [3] - The inclusion of CAR-T products is seen as a milestone that will positively impact the entire industry chain, with companies planning to expand domestic supplier partnerships to enhance supply chain efficiency [3]

受访专家表示，商保创新药目录的发布有利于促进商业健康险市场产品优化和创新，增强产品吸引力， 并助力推动多层次医疗保障体系建设。 提供创新药给付依据 今年6月份，国家医保局、国家卫生健康委发布《支持创新药高质量发展的若干措施》，提出"增设商业 健康保险创新药品目录"，要求适应多层次医疗保障体系发展需要，增设商保创新药目录，重点纳入创 新程度高、临床价值大、患者获益显著且超出基本医保保障范围的创新药，推荐商业健康保险和医疗互 助等多层次医疗保障体系参考使用。 具体来看，此次共有18家创新药企业的19个药品成功纳入首版商保创新药目录，包括消化道和代谢方面 的药物、抗肿瘤药及免疫调节剂、神经系统药物等。 对外经济贸易大学创新与风险管理研究中心副主任龙格对《证券日报》记者表示，商保创新药目录的发 布将为商业健康险市场提供明确、权威的创新药给付依据，有助于险企精准设计产品、控制理赔风险， 并推动开发覆盖前沿疗法的特色健康险。 而对于多层次医疗保障体系建设，商保创新药目录的推出也具有积极意义。北京大学应用经济学博士后 朱俊生对《证券日报》记者分析称，商保创新药目录的发布为医保体系提供了补充，通过引入部分高端 创新药品弥补了 ...

近日，国家医保局、人力资源社会保障部印发《国家基本医疗保险、生育保险和工伤保险药品目录（2025年）》（以下简 称"药品目录"）和《商业健康保险创新药品目录（2025年）》（以下简称"商保创新药目录"），上述两项目录将于2026年1月1 日起在全国范围内正式实施。其中，后者也是我国发布的首版商保创新药目录。 本报记者 杨笑寒 受访专家表示，商保创新药目录的发布有利于促进商业健康险市场产品优化和创新，增强产品吸引力，并助力推动多层次 医疗保障体系建设。 提供创新药给付依据 今年6月份，国家医保局、国家卫生健康委发布《支持创新药高质量发展的若干措施》，提出"增设商业健康保险创新药品 目录"，要求适应多层次医疗保障体系发展需要，增设商保创新药目录，重点纳入创新程度高、临床价值大、患者获益显著且 超出基本医保保障范围的创新药，推荐商业健康保险和医疗互助等多层次医疗保障体系参考使用。 具体来看，此次共有18家创新药企业的19个药品成功纳入首版商保创新药目录，包括消化道和代谢方面的药物、抗肿瘤药 及免疫调节剂、神经系统药物等。 对此，龙格认为，财险公司近年来的健康险保费收入增速较快，主要有三方面原因：一是凭借车险等强大线 ...

Core Insights - The release of the dual directory for national medical insurance and commercial insurance marks a significant step in building a multi-tiered medical security system, enhancing the accessibility of essential medications while promoting diverse development [1][2] Group 1: National Medical Insurance Directory - The new national medical insurance directory adds 114 new drugs, significantly improving coverage for key areas such as cancer, chronic diseases, mental health, rare diseases, and pediatric medications [1] - The approach of combining basic medical insurance with commercial insurance reflects the government's commitment to improving drug accessibility for the public and addressing diverse medication needs [1] Group 2: Commercial Insurance Innovation Directory - The first version of the commercial insurance innovation drug directory includes 19 drugs, primarily those with high innovation and clinical value [1] - The dual directory system maintains the principle of basic medical insurance while creating new pathways for high-value innovative drugs, thus encouraging pharmaceutical companies to invest in research and development [1] Group 3: Future Implications - The implementation of the dual directory is expected to create a win-win situation for multiple stakeholders, allowing patients to reduce their financial burden through commercial insurance while benefiting from policies supporting hospitalization for drugs in the commercial insurance innovation directory [2] - Future efforts are needed to break down data barriers between basic medical insurance and commercial insurance, establishing a one-stop settlement system to better leverage the roles of both insurance types in safeguarding public health [2]

Core Insights - The release of the 2025 National Medical Insurance Drug List and the first version of the Commercial Insurance Innovative Drug List marks a significant step in the construction of a multi-tiered medical security system, enhancing the accessibility of essential medications while diversifying options for patients [1] Group 1: National Medical Insurance Drug List - The updated National Medical Insurance Drug List includes 114 new drugs, significantly improving coverage for key areas such as cancer, chronic diseases, mental health, rare diseases, and pediatric medications [1] - The approach of combining basic medical insurance with commercial insurance reflects the government's commitment to improving drug accessibility for the public and addressing diverse medication needs [1] Group 2: Commercial Insurance Innovative Drug List - The first version of the Commercial Insurance Innovative Drug List includes 19 drugs, primarily those with high innovation and clinical value [1] - The dual-list system aims to balance the principles of basic insurance coverage while providing a pathway for high-value innovative drugs, thus encouraging pharmaceutical companies to invest in research and development [1] Group 3: Benefits of the Dual-List System - The implementation of the dual-list system is expected to create a win-win situation for multiple stakeholders, allowing patients to reduce their economic burden through commercial insurance reimbursement for certain medical expenses [1] - Drugs included in the Commercial Insurance Innovative Drug List can benefit from support policies for hospitalization, while commercial insurance can increase enrollment rates by including these innovative drugs [1] Group 4: Future Considerations - Future efforts are needed to break down data barriers between basic medical insurance and commercial insurance, establishing a one-stop settlement system to better leverage the roles of basic insurance and commercial insurance [2]

Core Insights - The National Healthcare Security Administration (NHSA) has released the updated National Basic Medical Insurance, Maternity Insurance, and Work Injury Insurance drug catalog, adding 114 new drugs, significantly enhancing coverage in key areas such as oncology [1][2] - The report highlights a successful establishment of a clear direction for supporting genuine and differentiated innovation through strategic purchasing [1] - The commercial health insurance drug catalog has been introduced, complementing the basic medical insurance and laying the foundation for a multi-tiered medical security system [3] Group 1: Drug Catalog Adjustments - The recent adjustment added 114 new drugs, including 50 class 1 innovative drugs, with an overall negotiation success rate of 88%, up from 76% in 2024 [2] - The total number of drugs in the catalog has increased to 3,253, with significant improvements in coverage for oncology, chronic diseases, mental illnesses, rare diseases, and pediatric medications [2] Group 2: Financial Implications - During the 14th Five-Year Plan period, the cumulative expenditure of the medical insurance fund exceeded 13 trillion yuan, benefiting nearly 20 billion patient visits [1] - Over the past seven years, 835 new drugs have been included in the medical insurance payment scope, with 149 of them being innovative drugs, and approximately 80% of innovative drugs being included within two years of market launch [1] Group 3: Commercial Health Insurance Developments - The first version of the commercial health insurance innovative drug catalog includes 19 drugs, focusing on high innovation, significant clinical value, and patient benefits beyond basic insurance coverage [3] - The introduction of the commercial health insurance catalog is expected to clarify the boundaries of basic medical insurance and promote the differentiated development of commercial health insurance [3]

Core Insights - The inclusion of innovative Alzheimer's disease (AD) treatments, Lecanemab and Donanemab, in China's first commercial health insurance innovative drug directory marks a significant breakthrough in the payment landscape for AD treatment [1][2] - The new "Medicare + Commercial Insurance" layered payment model aims to improve accessibility and affordability of high-cost innovative drugs for patients [2][4] - The commercial insurance directory reflects a shift in China's multi-tiered healthcare system, encouraging the payment for valuable innovations and enhancing the accessibility of innovative therapies for major diseases [1][4] Group 1: Policy and Market Changes - The National Healthcare Security Administration's introduction of the commercial health insurance innovative drug directory is a response to the high costs of breakthrough drugs and the limitations of the basic Medicare system [4][5] - The directory includes 19 drugs, with a focus on high-innovation and high-clinical-value treatments, including two significant AD drugs, indicating a broader strategy to address the economic burden of AD [5][6] - The commercial insurance directory is expected to stimulate demand for AD treatments, promoting early diagnosis and standardized treatment practices [2][6] Group 2: Economic Impact and Future Projections - The economic burden of AD in China is substantial, with annual costs reaching 1.1 trillion RMB in 2015, projected to rise to 3.2 trillion RMB by 2030 and 11.9 trillion RMB by 2050 [7] - The average cost of moderate to severe AD treatment is significantly higher than that of mild cases, necessitating a collaborative approach among Medicare, medical services, and pharmaceuticals to enhance drug accessibility [7][11] - The global AD drug market was valued at 23 billion RMB in 2020, with expectations to grow to 25.7 billion RMB by 2026, reflecting a compound annual growth rate of 1.5% [7] Group 3: Research and Development Landscape - The development of new AD drugs is a lengthy and costly process, averaging 10.5 years and requiring approximately 2.6 billion USD, with many candidates failing at various stages [8][10] - Current AD treatments in China include cholinesterase inhibitors and NMDA receptor antagonists, with the recent approval of new drugs like GV-971 [8][10] - The competitive landscape is shifting from a focus solely on drug efficacy to a broader ecosystem competition, influenced by the new commercial insurance directory [9][10] Group 4: Challenges and Recommendations - Despite the progress in including AD drugs in insurance coverage, barriers remain, such as the limited reach of commercial insurance and the need for a multi-layered payment model [11] - Establishing a dedicated AD patient database could facilitate faster efficacy validation and expand indications, reducing R&D risks for pharmaceutical companies [11] - As the incidence of AD increases with age, there is a pressing need for refined risk control mechanisms to ensure the sustainability of innovative drug payment systems [11]

Core Viewpoint - The inclusion of innovative Alzheimer's disease (AD) treatments, Lecanemab and Donanemab, in China's first commercial health insurance innovative drug directory marks a significant breakthrough in the payment model for high-cost treatments, transitioning from a single reliance on public insurance to a "public + commercial" layered payment system [2][6][10]. Group 1: Policy and Market Impact - The release of the first commercial health insurance innovative drug directory at the 2025 Innovative Drug High-Quality Development Conference includes two groundbreaking AD treatments, reflecting a critical step in enhancing the accessibility of innovative drugs within China's multi-tiered healthcare system [1][6]. - The new policy aims to alleviate the financial burden on patients by leveraging the flexibility of commercial insurance, which can provide customized coverage and complement public insurance, thereby reducing out-of-pocket expenses for patients [4][6]. - The commercial insurance directory includes 19 drugs, with a focus on high-innovation and high-clinical-value treatments, indicating a shift in the healthcare landscape towards supporting innovative therapies [6][10]. Group 2: Economic and Social Implications - The economic burden of AD in China is substantial, with annual costs for patients reaching approximately 1.1 trillion RMB in 2015, projected to rise to 3.2 trillion RMB by 2030 and 11.9 trillion RMB by 2050, highlighting the urgent need for effective treatment options [9][10]. - The low early diagnosis rate of AD in China, with 95% of patients diagnosed at moderate to severe stages, underscores the necessity for improved screening and treatment protocols to enhance early intervention [8][9]. - The introduction of the commercial insurance directory is expected to stimulate demand for AD treatments, promoting early diagnosis and standardized treatment practices, which are essential for addressing the public health challenges posed by an aging population [4][10]. Group 3: Research and Development Landscape - The development of new AD drugs is a lengthy and costly process, averaging 10.5 years and requiring approximately 2.6 billion USD, with many candidates failing at various stages of clinical trials [12][14]. - Despite the challenges, the competitive landscape for AD treatments is evolving, with domestic companies rapidly advancing their research efforts, while international firms continue to seek market entry in China [15][16]. - The recent failures of major pharmaceutical companies in clinical trials have not deterred investment in AD research; instead, they have accelerated the transformation of the AD treatment ecosystem, shifting focus from mere drug competition to a broader ecological competition [14][15].

Core Insights - The release of the dual directory for national medical insurance and commercial insurance marks a significant step in building a multi-tiered medical security system, enhancing the accessibility of essential medications while promoting diverse development [1][2] Group 1: National Medical Insurance Directory - The new national medical insurance drug list adds 114 new drugs, significantly improving coverage for key areas such as cancer, chronic diseases, mental health, rare diseases, and pediatric medications [1] - The dual directory approach maintains the principle of basic medical insurance while avoiding the impact of high-priced drugs on the insurance fund, thus encouraging the development of innovative drugs by companies [1] Group 2: Commercial Insurance Directory - The first version of the commercial insurance innovative drug directory includes 19 drugs, primarily those with high innovation and clinical value, reflecting the government's commitment to improving drug accessibility for the public [1] - The implementation of the dual directory is expected to create a win-win situation for multiple stakeholders, allowing patients to reduce their economic burden through commercial insurance while enhancing the enrollment rates for insurance providers [2] Group 3: Future Directions - Future efforts are needed to break down data barriers between basic medical insurance and commercial insurance, establishing a one-stop settlement system to better leverage the roles of both insurance types [2] - Continuous optimization and adjustment in practice are essential to ensure better health security for over 1.4 billion people [2]

Core Insights - The recent adjustment to the national medical insurance directory emphasizes support for innovative drugs, with 114 new drugs added, 111 of which are newly approved within the last five years, marking a historic high for innovative drugs not previously listed domestically or internationally [1][3] - The introduction of the "Commercial Health Insurance Innovative Drug Directory" includes 19 innovative drugs, primarily targeting high clinical value and significant patient benefits, which will help fill gaps in basic medical insurance coverage [1][4] Group 1: Innovative Drug Support - The adjustment to the basic medical insurance directory focuses on innovative drugs, with over 70% of the newly added drugs being domestically developed, showcasing China's advancements in certain therapeutic areas [1][3] - The percentage of newly listed drugs in the medical insurance directory that were launched within the last five years has increased from 32% in 2019 to 98% in 2024, indicating a strong shift towards supporting innovation [3] Group 2: Commercial Health Insurance Directory - The newly established "Commercial Health Insurance Innovative Drug Directory" serves as a guide for patients and insurers, allowing for better access to high-priced innovative drugs that are not covered by basic medical insurance [4][5] - The directory includes a significant number of cancer treatments, including CAR-T therapies, which are crucial for patients with difficult-to-treat conditions, thus addressing the financial burden on families [5][6] Group 3: Impact on Patients and Healthcare System - The inclusion of innovative drugs in the insurance directory is expected to reduce out-of-pocket expenses for patients, making treatments more accessible and encouraging hospitals to prescribe these high-cost medications without hesitation [6][7] - The dual-directory system aims to create a multi-tiered medical insurance framework, where basic insurance covers essential needs while commercial insurance supplements coverage for innovative treatments, ultimately reducing the financial burden on patients [7]